Selected publications
-
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
Breast Cancer Research and Treatment.
2016
Academic Article
GET IT
Times cited: 10 -
American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility.
Journal of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 200 -
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.
Cancer Prevention Research.
2012
Academic Article
GET IT
Times cited: 55 -
Breast cancer risk reduction.
JNCCN Journal of the National Comprehensive Cancer Network.
2010
Review
GET IT
Times cited: 21 -
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial.
The Lancet.
2010
Academic Article
GET IT
Times cited: 1195 - American Society of Clinical Oncology Clinical Practice Guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. Journal of Oncology Practice. 2009 Report GET IT
-
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Journal of Clinical Oncology.
2009
Review
GET IT
Times cited: 202 -
Breast cancer risk reduction: Clinical Practice Guidelines in Oncology™.
JNCCN Journal of the National Comprehensive Cancer Network.
2007
Conference Paper
GET IT
Times cited: 10 -
Progress in chemoprevention drug development: The promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - A plan to move forward.
Clinical Cancer Research.
2006
Review
GET IT
Times cited: 226